At a glance
- Originator Eli Lilly and Company
- Class Antiepileptic drugs; Isoquinolines; Neuroprotectants; Small molecules
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Huntington's disease
Most Recent Events
- 02 Oct 2000 No-Development-Reported for Alzheimer's disease in USA (PO)
- 02 Oct 2000 No-Development-Reported for Epilepsy in USA (PO)
- 02 Oct 2000 No-Development-Reported for Huntington's disease in USA (PO)